Analysis
Bolt Biotherapeutics has acquired Prana Therapies in a stock-for-stock reverse merger and secured a concurrent private placement to advance Prana's pipeline of multispecific antibodies, according to Pulse 2.0. The deal breaks down as:
- Private placement -- $120M raised upfront.
- Warrants -- up to $60M more if exercised, for potential total proceeds of $180M.
- Post-deal ownership -- former Prana shareholders about 51.7%, placement investors about 41.4%, pre-transaction Bolt shareholders the remaining 6.9%, fully diluted.
The structure is a reverse merger: Prana, the private company, becomes the effective majority owner of Bolt, the public shell, without running its own IPO process. Prana's lead program, PRA-216, is a fully human, half-life-extended bispecific antibody targeting IL-4Rα and TSLP, designed to block both downstream IL-4/IL-13 signaling and upstream TSLP -- two separate drivers of Type 2 inflammation. It's in Phase 2 trials for asthma, COPD and atopic dermatitis, with an additional Phase 2 in eosinophilic esophagitis planned, and Phase 1 healthy-volunteer data presented at the 2026 European Respiratory Society meeting showed good tolerability and durable activity on inflammation biomarkers. Prana co-founder and former CEO Sheila Gujrathi becomes Bolt's chief strategy officer and joins its board; Willie Quinn remains Bolt's CEO.
“- Warrants -- up to $60M more if exercised, for potential total proceeds of $180M.”
Who's Backing a Reverse Merger Over an IPO
The placement drew a dense list of biotech and crossover investors: Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Coastlands Capital, Eventide Asset Management, Casdin Capital, Curie.Bio, SilverArc Capital, Soleus Capital, Deviation Capital and YK Bioventures, placed through Jefferies, TD Cowen, Stifel and LifeSci Capital. That roster overlaps heavily with the investor base behind this week's other inflammation and oncology financings -- Pathos AI's Bristol Myers Squibb-led Series E and Star Therapeutics' OrbiMed-and-Janus-Henderson round both drew from the same pool of specialist biotech funds, a sign capital is concentrating among a small number of repeat backers even as deal volume stays high.
The $120 million base raise, against a potential $180 million with warrants, is designed to fund Bolt into 2028 and through readouts across all four of PRA-216's ongoing trials -- a longer runway than many small-cap biotechs secure in a single round. The catch is timing: patient data from those trials isn't expected until Q2 2027 at the earliest, so investors are committing capital more than a year before any readout that could move the stock, and reverse mergers carry their own execution risk if shareholder votes or Nasdaq listing requirements don't go as planned.
Prana's next pipeline asset, an IL-31 bispecific for atopic dermatitis, won't post first-in-human data until the second half of 2027 -- a second catalyst investors are funding years ahead of any readout, the same bet they just made on PRA-216.